Showing 6891-6900 of 10618 results for "".
- Workflow Redesign Improved Weight Care in Primary Care Trialhttps://reachmd.com/news/workflow-redesign-improved-weight-care-in-primary-care-trial/2486863/Key Takeaways PATHWEIGH was associated with a modest population-level change in weight trajectory during routine primary care. The intervention phase was linked to more discernable weight-related care and larger weight reductions among patients who rec
- Niraparib Plus Abiraterone in HRR-Deficient mCSPChttps://reachmd.com/news/niraparib-plus-abiraterone-in-hrr-deficient-mcspc/2486864/Key Takeaways Longer radiographic progression-free survival was observed with niraparib plus abiraterone across the prespecified BRCA, HRR effector, and intention-to-treat populations. Overall survival remained immature and numerically favored nirapari
- Review Charts Anatomically Driven Advances in East Asian Rhinoplastyhttps://reachmd.com/news/review-charts-anatomically-driven-advances-in-east-asian-rhinoplasty/2486869/A recent review published online in Journal of Craniofacial Surgery examines the evolution of nasal tip rhinoplasty in East Asia, highlighting a transition from imported Western techniques to regionally tailored innovations grounded in anatomic and cultural considerations. Nasal t
- Cadonilimab Subgroup Analyses in COMPASSION-16https://reachmd.com/news/cadonilimab-subgroup-analyses-in-compassion-16/2486825/Key Takeaways Across the analyzed subgroups, progression-free survival consistently favored cadonilimab. Overall survival was also reported as prolonged with the addition of cadonilimab. The subgroup framework spanned prespecified clinical and
- Tucidinostat Plus R-CHOP Improves Outcomes in Double-Expressor DLBCLhttps://reachmd.com/news/tucidinostat-plus-r-chop-improves-outcomes-in-double-expressor-dlbcl/2486836/Key Takeaways Tucidinostat plus R-CHOP was associated with improved event-free survival versus placebo plus R-CHOP in newly diagnosed MYC/BCL2 double-expressor DLBCL. The tucidinostat regimen was also associated with a higher complete response rate at
- Atezolizumab Plus FOLFOX Improves DFS in Stage III dMMR Colon Cancerhttps://reachmd.com/news/atezolizumab-plus-folfox-improves-dfs-in-stage-iii-dmmr-colon-cancer/2486784/Key Takeaways The phase 3 randomized trial compared atezolizumab plus mFOLFOX6 with mFOLFOX6 alone after resection in stage III dMMR colon cancer. Disease-free survival was higher and recurrence or death was lower with the atezolizumab-containing regim
- Secukinumab In SELUNE: Phase III Lupus Nephritis Readouthttps://reachmd.com/news/secukinumab-in-selune-phase-iii-lupus-nephritis-readout/2486777/Key Takeaways Complete renal response at week 52 was lower with secukinumab than with placebo. No differences were seen across secondary endpoints, and treatment-emergent adverse events were similar between groups. A planned futility analysis
- Fremanezumab Trial Shows Benefit in Pediatric Episodic Migrainehttps://reachmd.com/news/fremanezumab-trial-shows-benefit-in-pediatric-episodic-migraine/2486788/Key Takeaways Fremanezumab was associated with a larger reduction in monthly migraine days than placebo during the randomized 3-month comparison. Days with at least moderate headache severity also declined more, and 47.2% of fremanezumab-treated partic
- High-Dose Oral Rifampin in Adults With Tuberculous Meningitishttps://reachmd.com/news/high-dose-oral-rifampin-in-adults-with-tuberculous-meningitis/2486783/Key Takeaways Adults assigned to the higher cumulative rifampin dose did not show a survival advantage at 6 months. Drug-induced liver injury was reported more often with intensified rifampin, and no deaths from liver injury were reported. The
- Study Evaluates Buccal Fat Pad Flap in Complex Facial Reconstructionhttps://reachmd.com/news/study-evaluates-buccal-fat-pad-flap-in-complex-facial-reconstruction/2486791/A prospective cohort study published online in Aesthetic Plastic Surgery evaluated the reconstructive utility of the buccal fat pad flap in patients undergoing permanent filler removal followed by deep plane facelift. Conducted at a single center in Cairo between 2016 and 2022, the study